Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Debt to Equity (2023 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Debt to Equity for 3 consecutive years, with $16.1 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Debt to Equity rose 305.37% year-over-year to $16.1, compared with a TTM value of $16.1 through Dec 2025, up 305.37%, and an annual FY2025 reading of $16.1, up 305.37% over the prior year.
  • Debt to Equity was $16.1 for Q4 2025 at Xeris Biopharma Holdings, up from -$254.9 in the prior quarter.
  • Across five years, Debt to Equity topped out at $16.1 in Q4 2025 and bottomed at -$254.9 in Q3 2025.
  • Average Debt to Equity over 3 years is -$23.92, with a median of -$0.32 recorded in 2024.
  • Peak annual rise in Debt to Equity hit 305.37% in 2025, while the deepest fall reached 51905.27% in 2025.
  • Year by year, Debt to Equity stood at -$28.15 in 2023, then surged by 72.16% to -$7.84 in 2024, then surged by 305.37% to $16.1 in 2025.
  • Business Quant data shows Debt to Equity for XERS at $16.1 in Q4 2025, -$254.9 in Q3 2025, and -$11.33 in Q2 2025.